These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37551065)

  • 1. Dual Synergistic Tumor-Specific Polymeric Nanoparticles for Efficient Chemo-Immunotherapy.
    Xiang J; Liu K; Xu H; Zhao Z; Piao Y; Shao S; Tang J; Shen Y; Zhou Z
    Adv Sci (Weinh); 2023 Oct; 10(29):e2301216. PubMed ID: 37551065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
    Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
    ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy.
    Qi J; Jia S; Kang X; Wu X; Hong Y; Shan K; Kong X; Wang Z; Ding D
    Adv Mater; 2022 Aug; 34(31):e2203309. PubMed ID: 35704513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
    Liu J; Zhao Z; Qiu N; Zhou Q; Wang G; Jiang H; Piao Y; Zhou Z; Tang J; Shen Y
    Nat Commun; 2021 Apr; 12(1):2425. PubMed ID: 33893275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
    Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
    J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
    Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
    Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binary regulation of the tumor microenvironment by a pH-responsive reversible shielding nanoplatform for improved tumor chemo-immunotherapy.
    Sun X; Zhang J; Zhao X; Yang C; Shi M; Zhang B; Hu H; Qiao M; Chen D; Zhao X
    Acta Biomater; 2022 Jan; 138():505-517. PubMed ID: 34798317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway.
    Liu Z; Zhao L; Liu H; Dong N; Zhou N; Zhang Y; Yin T; He H; Gou J; Tang X; Yang L; Gao S
    Int J Pharm; 2022 Nov; 628():122361. PubMed ID: 36332828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy.
    Luo F; Yang G; Bai X; Yuan D; Li L; Wang D; Lu X; Cheng Y; Wang Y; Song X; Zhao Y
    Cell Chem Biol; 2023 Nov; 30(11):1390-1401.e6. PubMed ID: 37944524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer.
    Liu H; Xu C; Meng M; Li S; Sheng S; Zhang S; Ni W; Tian H; Wang Q
    Acta Biomater; 2022 May; 144():132-141. PubMed ID: 35307591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.
    Yu Y; Li J; Song B; Ma Z; Zhang Y; Sun H; Wei X; Bai Y; Lu X; Zhang P; Zhang X
    Biomaterials; 2022 Jan; 280():121312. PubMed ID: 34896861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.